Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.13p
   
  • Change Today:
    -0.055p
  • 52 Week High: 3.42p
  • 52 Week Low: 0.85p
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 2,365,381
  • Market Cap: £8.85m
  • RiskGrade: 328

ImmuPharma upbeat after meeting with US partner Avion

By Josh White

Date: Friday 11 Nov 2022

LONDON (ShareCast) - (Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.
The AIM-traded firm said Avion confirmed its support for the Lupuzor clinical programme in lupus at the meeting, following the receipt of a written response from the US Food and Drug Administration (FDA) to the 'type C' meeting in September.

In its written response, the FDA provided "significant and extremely valuable" guidance on the study protocol, that could be amended, to improve the regulatory outcome.

The board said it primarily focussed on a recommendation to explore higher dosing levels, given the robust safety profile of Lupuzor, than were used in the clinical programme so far, to enhance the probability of meeting the primary endpoint of statistically significant efficacy.

ImmuPharma and Avion, together with external advisors, were now preparing a proposed updated clinical programme.

The company said the update was considering either a phase 2 dose ranging study to identify the optimum dose level, followed by a phase 3 study with that optimum dose, or alternatively a phase 2 and 3 adaptive study which would encompass the same dose ranging within one continuous study.

It said the chosen route would be agreed with the FDA, with further details on the study design and progress to be communicated once the FDA was consulted and a response provided.

ImmuPharma said it also agreed to explore the opportunity of a mutually-beneficial route to allow ImmuPharma to introduce certain Avion products into the European market.

If that was successful, it would generate top-line product sales revenue for the first time in ImmuPharma's history and contribute net positive cash flow to the company.

In turn, the board said the firm had identified an established European partner that could provide the infrastructure to market and distribute the products.

Discussions were to be progressed as to the legal, regulatory and commercial aspects of such a collaboration, the directors added.

"We have had extremely positive discussions with Avion over the last month and, following receipt of the written response from the FDA, we have agreed to redesign the clinical program for Lupuzor to encompass the recommendations from the FDA, with a view to enhancing the probability of success," said chief executive officer Tim McCarthy.

"In addition, our discussions have developed the potential of a much broader collaboration whereby we would be working in partnership to introduce certain Avion products into the European market."

At 1300 GMT, shares in ImmuPharma were down 13.77% at 2.85p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.13p
Change Today -0.055p
% Change -2.52 %
52 Week High 3.42p
52 Week Low 0.85p
Volume 2,365,381
Shares Issued 416.44m
Market Cap £8.85m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average
18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average
Price Trend
4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average
47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:17 14,000 @ 2.08p
16:13 22,386 @ 2.20p
16:13 9,454 @ 2.20p
16:13 10,000 @ 2.15p
16:12 15,000 @ 2.15p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page